Related Experiment Videos
Abstract:
The RET proto-oncogene has not only conclusively been identified as responsible for the three subtypes of the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN-2) but also shown to be involved in the molecular evolution of sporadic medullary and papillary thyroid carcinoma as well as Hirschsprung's disease. A variety of recent studies have elucidated the pathophysiological mechanisms leading to neoplastic disease and we now understand that dominant activating germline mutations lead to MEN-2A, MEN-2B, and familial MTC; somatic mutations to sporadic medullary thyroid carcinoma; RET rearrangements to papillary thyroid carcinoma; and inactivating alterations to Hirschsprung's disease. The clinical significance, however, of RET alterations especially in sporadic thyroid tumors is still controversial and therapeutic concepts in MEN-2 gene carriers only start to emerge. This article is a short summary of the recent findings on the structure and physiology of the RET proto-oncogene and its role in familial and sporadic thyroid cancer.
Insights
The RET proto-oncogene drives multiple endocrine neoplasia type 2 (MEN-2) and various thyroid cancers. Understanding RET gene mutations is crucial for diagnosing and potentially treating these inherited and sporadic conditions.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- The RET proto-oncogene is implicated in multiple endocrine neoplasia type 2 (MEN-2) and thyroid cancers.
- RET gene alterations are linked to both inherited and sporadic forms of medullary and papillary thyroid carcinoma.
- RET gene mutations also play a role in Hirschsprung's disease.
Purpose of the Study:
- To summarize recent findings on the RET proto-oncogene's structure and physiology.
- To elucidate the role of RET alterations in familial and sporadic thyroid cancer.
- To discuss the pathophysiological mechanisms underlying RET-associated diseases.
Main Methods:
- Review of recent studies on RET proto-oncogene function.
- Analysis of genetic alterations (germline and somatic mutations, rearrangements) in RET.
- Correlation of RET alterations with specific disease subtypes (MEN-2A, MEN-2B, MTC, papillary thyroid carcinoma, Hirschsprung's disease).
Main Results:
- Dominant activating germline mutations in RET cause MEN-2A, MEN-2B, and familial medullary thyroid carcinoma (MTC).
- Somatic RET mutations are found in sporadic medullary thyroid carcinoma.
- RET rearrangements are associated with papillary thyroid carcinoma, and inactivating alterations with Hirschsprung's disease.
Conclusions:
- RET proto-oncogene alterations are key drivers in MEN-2 syndromes and various thyroid cancers.
- The specific type of RET alteration dictates the resulting pathology, from inherited syndromes to sporadic tumors.
- Further research is needed to clarify the clinical significance of RET alterations in sporadic thyroid tumors and develop targeted therapies.